A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®
An Open-Label, Randomized, Single Cross-over Study of Warm Compress Versus Usual Injection Site Preparation on Local Injection Site Reactions Among Persons With MS Who Perform Daily Injections of Copaxone®.
Sponsor: Teva Neuroscience, Inc.
Listed as NCT00239993, this PHASE4 trial focuses on Multiple Sclerosis and remains completed. Sponsored by Teva Neuroscience, Inc., it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Aug 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Teva Neuroscience, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .